PDS Biotechnology Corporation
PDSB
$0.29
-$0.01-2.33%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.23M | 3.06M | 2.27M | 3.56M | 3.41M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.50M | 6.52M | 6.67M | 8.14M | 7.62M |
| Operating Income | -6.50M | -6.52M | -6.67M | -8.14M | -7.62M |
| Income Before Tax | -9.75M | -7.35M | -7.56M | -9.01M | -9.43M |
| Income Tax Expenses | -- | -- | 0.00 | -- | -- |
| Earnings from Continuing Operations | -9.75M | -7.35M | -7.56M | -9.01M | -9.43M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.75M | -7.35M | -7.56M | -9.01M | -9.43M |
| EBIT | -6.50M | -6.52M | -6.67M | -8.14M | -7.62M |
| EBITDA | -6.48M | -6.51M | -6.66M | -8.13M | -7.61M |
| EPS Basic | -0.18 | -0.13 | -0.15 | -0.19 | -0.21 |
| Normalized Basic EPS | -0.11 | -0.08 | -0.09 | -0.12 | -0.13 |
| EPS Diluted | -0.18 | -0.13 | -0.15 | -0.19 | -0.21 |
| Normalized Diluted EPS | -0.11 | -0.08 | -0.09 | -0.12 | -0.13 |
| Average Basic Shares Outstanding | 55.66M | 55.50M | 51.59M | 46.87M | 45.90M |
| Average Diluted Shares Outstanding | 55.66M | 55.50M | 51.59M | 46.87M | 45.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |